Meta Description:<\/b><\/p>\n
UK clinical monograph on NPP 100 (nandrolone phenylpropionate 100 mg\/mL) detailing short-acting ester pharmacology, progestogenic activity, adverse effects, and Class C regulatory status.<\/p>\n
NPP 100 is an unregulated commercial trade formulation representing a short-to-medium-acting injectable preparation of the synthetic anabolic-androgenic steroid (AAS) nandrolone phenylpropionate (chemically designated as <\/span>$17\\beta\\text{-(3-phenylpropanoyloxy)estr-4-en-3-one}$<\/span>, 19-nortestosterone <\/span>$17\\beta\\text{-phenylpropionate}$<\/span>, or nandrolone phenpropionate).<\/span> The drug product is formulated to deliver a target concentration of $100\\text{ mg\/mL}$<\/span> of nandrolone phenylpropionate dissolved in an intramuscular lipophilic vehicle (typically refined sesame, arachis, or grapeseed oil combined with antimicrobial benzyl alcohol and solubilizing co-solvents such as benzyl benzoate). Structurally, nandrolone belongs to the 19-norandrostane ($19\\text{-nor}$<\/span>) steroid family, characterized by the absence of the carbon-19 angular methyl group found in endogenous testosterone. Esterification of the $17\\beta\\text{-hydroxyl}$<\/span> functional group with 3-phenylpropionic (hydrocinnamic) acid yields a 9-carbon aromatic-aliphatic ester moiety. This structural modification confers intermediate lipophilicity, resulting in a release profile from intramuscular depots that is considerably more rapid than that of the decanoate ester (e.g., Deca-Durabolin), while remaining slower than unesterified steroids.<\/p>\n Within the United Kingdom regulatory framework, NPP 100 holds no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). Although pharmaceutical-grade nandrolone phenylpropionate was historically licensed under the trade name Durabolin (commonly at lower concentrations of <\/span>$25\\text{ to }50\\text{ mg\/mL}$<\/span>) for the palliative management of advanced post-menopausal mammary carcinoma and refractory catabolic states, all human medicinal licenses in the UK have been discontinued or withdrawn in favor of targeted endocrine therapeutics.<\/span> Under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, nandrolone phenylpropionate is categorized as a Class C, Schedule 4 (Part II) controlled drug. It is not catalogued in the British National Formulary (BNF) as an approved NHS pharmaceutical entity. Formulations bearing the trade style “NPP 100” originate entirely from illicit underground laboratories (UGLs) and unregulated grey-market supply networks, carrying substantial clinical risks of chemical non-sterility, particulate matter, carrier oil oxidation, and significant dosage inaccuracies.<\/p>\n The pharmacodynamic profile of NPP 100 is governed by intracellular androgen receptor transactivation, altered peripheral enzymatic reduction, intrinsic progestogenic signaling, and potent neuroendocrine feedback:<\/p>\n Androgen Receptor (AR) Agonism and Myofibrillar Anabolism:<\/b> Following intramuscular injection, circulating and tissue non-specific esterases cleave the phenylpropionate ester to liberate biologically active, free nandrolone. Free nandrolone binds to intracellular androgen receptors in skeletal myocytes, osteoblasts, and bone marrow stromal cells with a higher affinity than endogenous testosterone. The ligand-receptor complex translocates into the cell nucleus, where it binds to androgen response elements (AREs) on genomic DNA. This drives RNA polymerase II-directed transcription, stimulating myofibrillar protein synthesis, promoting intracellular nitrogen retention, and upregulating local muscular expression of insulin-like growth factor-1 (IGF-1). Its anabolic-to-androgenic ratio is estimated at approximately $37:125$<\/span> (relative to testosterone at $100:100$<\/span>).<\/p>\n<\/li>\n Differential $5\\alpha\\text{-Reductase}$<\/span> Biotransformation:<\/b> In androgen-responsive tissues expressing $5\\alpha\\text{-reductase}$<\/span> isoenzymes (such as the prostate gland, scalp hair follicles, and dermis), nandrolone is metabolized into $5\\alpha\\text{-dihydronandrolone}$<\/span> (DHN). Unlike testosterone, which converts to the markedly more potent androgen dihydrotestosterone (DHT), DHN exhibits substantially lower binding affinity for the androgen receptor than parent nandrolone. This dampens local androgenic signaling in the prostate and scalp relative to skeletal muscle; however, this relative tissue selectivity is easily overwhelmed at supraphysiological dosages.<\/p>\n<\/li>\n Attenuated Aromatisation Rate:<\/b> The structural removal of the C-19 methyl group creates steric resistance against interaction with the cytochrome P450 aromatase enzyme complex ($CYP19A1$<\/span>). Nandrolone is converted into oestrogenic metabolites ($17\\beta\\text{-oestradiol}$<\/span>) at approximately $20\\%$<\/span> of the rate observed with equivalent titers of testosterone.<\/p>\n<\/li>\n Progesterone Receptor (PR) Agonism:<\/b> Nandrolone exhibits intrinsic, moderate binding affinity for the human progesterone receptor (acting as a partial-to-full PR agonist). PR activation stimulates glandular mammary tissue proliferation and promotes local tissue fluid retention, which can act synergistically with circulating oestrogens to trigger marked gynaecomastia.<\/span><\/p>\n<\/li>\n Profound Hypothalamic-Pituitary-Gonadal (HPG) Axis Suppression:<\/b> Through combined AR and PR negative feedback mechanisms at the hypothalamic arcuate nucleus and anterior pituitary gonadotrophs, nandrolone potently suppresses gonadotropin-releasing hormone (GnRH), luteinising hormone (LH), and follicle-stimulating hormone (FSH) release. This results in rapid shutdown of endogenous testicular testosterone production.<\/p>\n<\/li>\n<\/ul>\n NPP 100 possesses no approved clinical indications in the United Kingdom. No randomized, double-blind, multicentre Phase I\u2013III clinical trials conforming to MHRA statutory criteria have evaluated this $100\\text{ mg\/mL}$<\/span> formulation for therapeutic safety, dosage precision, or clinical efficacy.<\/p>\n The National Institute for Health and Care Excellence (NICE) does not endorse, recommend, or integrate NPP 100 into any clinical management pathway. It is entirely absent from clinical guidelines governing osteoporosis, renal disease-associated anaemia, or male hypogonadism. Contemporary UK clinical pathways utilize targeted therapies, including bisphosphonates, denosumab, and recombinant human erythropoietin (epoetin alfa\/beta, darbepoetin alfa).<\/p>\n The practical application of NPP 100 is confined entirely to illicit athletic performance enhancement, competitive bodybuilding, and forensic doping toxicology. In these unapproved settings, it is sought for:<\/p>\n Accrual of dense skeletal muscle mass and positive nitrogen balance with more rapid clearance kinetics than nandrolone decanoate.<\/span><\/p>\n<\/li>\n Alleviation of joint discomfort and connective tissue strain via fluid retention in synovial structures and collagen synthesis stimulation.<\/p>\n<\/li>\n Augmentation of circulating red cell mass and muscular recovery velocity between intense conditioning bouts.<\/p>\n<\/li>\n<\/ul>\n NPP 100 holds no status within the NHS drug tariff, cannot be prescribed on NHS prescription forms (FP10), and must never be substituted for licensed testosterone replacement therapy (TRT).<\/p>\n Because NPP 100 is formulated as an oily solution intended for deep intramuscular administration, its pharmacokinetic disposition reflects intermediate depot release characteristics:<\/p>\n Absorption and Depot Cleavage:<\/b> Following intramuscular injection into gluteal, deltoid, or vastus lateralis sites, the lipophilic steroid ester forms an intramuscular reservoir. The 3-phenylpropionate ester chain partitions across the oil-water interface into extracellular fluids significantly faster than decanoate esters. Free nandrolone is liberated via systemic and local non-specific esterases. Peak serum concentrations ($T_{max}$<\/span>) are typically reached within 24 to 36 hours post-injection.<\/p>\n<\/li>\n Distribution:<\/b> Free nandrolone circulates in the blood bound to serum proteins. It exhibits low affinity for sex hormone-binding globulin (SHBG) compared to testosterone and DHT, circulating predominantly bound to human serum albumin or in an unbound active state. Its lipophilicity results in an extensive volume of distribution ($V_d$<\/span>), distributing into adipose tissue, skeletal muscle, and across the blood-brain barrier.<\/p>\n<\/li>\n Biotransformation:<\/b> Nandrolone undergoes extensive hepatic metabolism, involving reduction of the 3-keto group, oxidation of the $17\\beta\\text{-hydroxyl}$<\/span> group, and Phase II glucuronidation and sulfation. The primary urinary metabolites identified in human excretion profiles are 19-norandrosterone (19-NA) and 19-noretiocholanolone (19-NE), conjugated to glucuronic acid.<\/span><\/p>\n<\/li>\n Elimination:<\/b> Systemic elimination is predominantly renal, with over 70\u201380% of excreted dose metabolites cleared in the urine as polar conjugates; the remainder is eliminated via biliary secretion into faeces. The apparent terminal elimination half-life (<\/span>$t_{1\/2}$<\/span>) of the phenylpropionate ester depot in humans is approximately 2.5 to 4.5 days (necessitating administration every 2 to 3 days in illicit regimens to avoid substantial plasma trough fluctuations).<\/span> Although the active parent compound clears from circulation much faster than nandrolone decanoate (within 7 to 10 days post-cessation), trace conjugated metabolites (notably 19-norandrosterone) can remain detectable in urine via gas chromatography-mass spectrometry (GC-MS) or LC-MS\/MS anti-doping screens for up to 12 to 18 months.<\/span><\/p>\n<\/li>\n<\/ul>\n The primary physiological effect reported in non-medical contexts is rapid skeletal muscle hypertrophy accompanied by nitrogen retention, joint comfort enhancement, and body weight gain. However, its supraphysiological administration presents severe multi-system adverse effects:<\/p>\n Cardiovascular Toxicity:<\/b><\/p>\n Severe atherogenic dyslipidaemia: marked suppression of high-density lipoprotein cholesterol (HDL-C; often dropping below $0.4\\text{ mmol\/L}$<\/span>) and elevation of low-density lipoprotein cholesterol (LDL-C), accelerating arterial atherogenesis.<\/p>\n<\/li>\n Vascular dysfunction: impairment of endothelial nitric oxide synthesis and increased arterial stiffness, causing systemic hypertension.<\/p>\n<\/li>\n Myocardial remodeling: pathological left ventricular concentric hypertrophy (LVH), myocardial fibrosis, and subclinical diastolic dysfunction, predisposing users to arrhythmias and early-onset heart failure.<\/p>\n<\/li>\n Polycythaemia: erythropoietic stimulation elevating haematocrit ($>52\\text{–}54\\%$<\/span>) and blood viscosity, significantly increasing risks of thromboembolism (deep vein thrombosis, pulmonary embolism, ischaemic stroke).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Endocrine and Gonadal Axis Suppression:<\/b><\/p>\n Severe hypogonadotrophic hypogonadism: due to potent AR and PR negative feedback, endogenous testosterone production, LH, and FSH are rapidly shut down, causing testicular atrophy, azoospermia, persistent erectile dysfunction, and loss of libido (often termed “deca dick” in consumer contexts).<\/p>\n<\/li>\n Progestogenic Gynaecomastia: stimulation of mammary glandular tissue proliferation, which can occur even with controlled circulating oestrogen levels.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Neuropsychiatric Disturbances:<\/b><\/p>\n Anhedonia, depressive symptoms, increased anxiety, emotional blunting, and mood volatility, exacerbated by profound central neurosteroid and dopaminergic alterations during and after use.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Injection Site and Local Toxicities:<\/b><\/p>\n Because the shorter ester requires frequent intramuscular injections (every 2 to 3 days), users face heightened cumulative trauma, local pain, induration, sterile abscess formation, bacterial myositis, and foreign-body granulomas, alongside pulmonary oil microembolism (“steroid cough”) if inadvertently injected into a venule.<\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n Given its non-approved clinical status, high potency, and extreme adverse effect profile, NPP 100 requires strict adherence to pharmacological contraindications and harm-minimisation standards:<\/p>\n Contraindications:<\/b><\/p>\n Absolute Contraindication in All Humans: The formulation is an unregulated, illicit chemical preparation lacking medicinal safety approval.<\/p>\n<\/li>\n Malignancy: Absolute contraindication in prostate adenocarcinoma, male breast carcinoma, or any hormone-sensitive neoplasm.<\/p>\n<\/li>\n Pre-existing Cardiovascular Disease: Absolute contraindication in severe coronary artery disease, history of myocardial infarction, heart failure, or uncontrolled hypertension.<\/p>\n<\/li>\n Hepatic or Renal Disease: Contraindicated in chronic kidney disease or baseline liver dysfunction.<\/p>\n<\/li>\n Pregnancy and Lactation: Absolute contraindication; severe virilisation of female fetuses, embryotoxicity, and teratogenicity.<\/p>\n<\/li>\n Paediatric Population: Contraindicated in children and adolescents due to premature epiphyseal closure and stunted adult stature.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Drug Interactions:<\/b><\/p>\n Anticoagulants (e.g., Warfarin, DOACs):<\/i> Anabolic steroids enhance anticoagulant sensitivity by altering hepatic clotting factor synthesis, increasing haemorrhagic risk.<\/p>\n<\/li>\n Insulin and Oral Hypoglycaemic Agents:<\/i> Nandrolone alters peripheral insulin sensitivity; co-administration can trigger unexpected hypoglycaemic episodes, requiring antidiabetic dosage titration.<\/p>\n<\/li>\n Other Anabolic and Stimulant Agents:<\/i> Concurrent stacking with other AAS, selective androgen receptor modulators (SARMs), or thermogenic stimulants significantly amplifies cardiovascular, hepatic, and psychiatric morbidity.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Clinical Precautions and Harm Minimisation:<\/b><\/p>\n Cardiovascular Alarm Symptoms (“Red Flags”): Patients presenting with central crushing chest pain, unexplained acute breathlessness, sudden focal neurological deficits, or acute unilateral leg swelling require immediate emergency (999\/A&E) transfer.<\/p>\n<\/li>\n Diagnostic Workup for Illicit AAS Users: Clinicians encountering individuals using illicit nandrolone phenylpropionate should perform a structured clinical risk assessment: 12-lead ECG, blood pressure evaluation, full blood count (monitoring haematocrit), comprehensive lipid profile (total cholesterol, HDL-C, LDL-C, triglycerides), liver function tests, renal parameters (urea, electrolytes, eGFR), and an early-morning endocrine panel (total testosterone, SHBG, LH, FSH, prolactin, and oestradiol).<\/p>\n<\/li>\n Clinical Cessation Support: Clinicians should counsel patients directly on the health hazards of unregulated UGL steroids, support compound cessation, and refer to endocrinology services for the management of prolonged post-AAS hypogonadotrophic hypogonadism when indicated.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n 2. Mechanism of Action and Pharmacodynamics<\/h2>\n
\n
3. Approved UK Clinical Indications and Therapeutic Scope<\/h2>\n
\n
4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n
\n
5. Physiological Effects and Adverse Event Spectrum<\/h2>\n
\n
\n
\n
\n
\n
6. Contraindications, Drug Interactions, and Clinical Precautions<\/h2>\n
\n
\n
\n
\n